Episteme Prognostics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$5.64M
- Investors
-
1
Episteme Prognostics General Information
Description
Developer of a diagnostic platform designed for predicting chemotherapy response in cancer patients. The company's technology utilizes proprietary chromatin accessibility profiling and epigenetic biomarker identification to analyze gene regulatory elements, providing oncology clinics with diagnostic microarrays, prognostic scoring systems, and companion diagnostics, enabling medical professionals to identify effective treatment paths and avoid unnecessary interventions.
Contact Information
Website
www.epistemedx.comCorporate Office
- 30 River Road
- Apartment 8 East
- New York, NY 10044
- United States
Corporate Office
- 30 River Road
- Apartment 8 East
- New York, NY 10044
- United States
Episteme Prognostics Timeline
Episteme Prognostics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Seed Round | 04-Sep-2026 | $5.64M | Completed | Startup | ||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Seed Round | 13-Apr-2023 | $4.11M | $4.11M | Completed | Startup |
Episteme Prognostics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-2 | ||||||||
| Seed-1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Episteme Prognostics Patents
Episteme Prognostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026024826-A1 | Combination methods for profiling genetic mutations and chromatin accessibility | Pending | 25-Jul-2024 | ||
| AU-2024243779-A1 | Arrays targeting differentially accessible chromatin regions using quantitative polymerase chain reaction | Pending | 05-Apr-2023 | ||
| EP-4689189-A1 | Arrays targeting differentially accessible chromatin regions using quantitative polymerase chain reaction | Pending | 05-Apr-2023 | ||
| US-20240344143-A1 | Arrays targeting differentially accessible chromatin regions using quantitative polymerase chain reaction | Pending | 05-Apr-2023 | ||
| WO-2024211731-A1 | Arrays targeting differentially accessible chromatin regions using quantitative polymerase chain reaction | Inactive | 05-Apr-2023 | C12Q1/6886 |
Episteme Prognostics Signals
Episteme Prognostics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| DRIVEN Accelerator Hub | Accelerator/Incubator |
Episteme Prognostics FAQs
-
When was Episteme Prognostics founded?
Episteme Prognostics was founded in 2021.
-
Where is Episteme Prognostics headquartered?
Episteme Prognostics is headquartered in New York, NY.
-
What is the size of Episteme Prognostics?
Episteme Prognostics has 2 total employees.
-
What industry is Episteme Prognostics in?
Episteme Prognostics’s primary industry is Decision/Risk Analysis.
-
Is Episteme Prognostics a private or public company?
Episteme Prognostics is a Private company.
-
What is Episteme Prognostics’s current revenue?
The current revenue for Episteme Prognostics is .
-
How much funding has Episteme Prognostics raised over time?
Episteme Prognostics has raised $9.8M.
-
Who are Episteme Prognostics’s investors?
DRIVEN Accelerator Hub has invested in Episteme Prognostics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process